ForSight Robotics has completed a $55 million Series A round to advance what it's calling the world's first surgical platform for fully robotic cataract surgery: ORYOM.
ForSight said its flagship robotic platform will increase accessibility to ophthalmic surgery procedures worldwide. The funding will be used to accelerate the development of the ORYOM platform in clinical trials. The company is working on other preventable ophthalmic diseases that can benefit from the accuracy of a robotics platform and advanced visualization such as retinal diseases and glaucoma among others.
The Adani Group led the funding round alongside existing investors Eclipse Ventures and Mithril Capital. A number of new investors, including Provenio Capital, Precision Capital, Reiya Ventures, the Ljungstrom family office, and other prominent private investors also joined the round. Following an initial $10 million mega-seed round last year, ForSight has advanced its technological capabilities and doubled in size. The ORYOM platform has already been used successfully in multiple cataract procedures on an animal eye model by a number of ophthalmic surgeons.
ORYOM – which means "daylight" in Hebrew – uses technologies in microsurgical robotics, computer visualization and machine learning. The platform will automate the complex subtleties of ophthalmic surgery to treat the diseases underlying preventable blindness with an intuitive platform.
"We are pleased to be able to advance our technology with this investment to bring robotics into the world of ophthalmic surgery to help millions of patients who have to wait unnecessarily for procedures while their eyesight deteriorates," says ForSight Chief Executive Officer and Co-Founder Dr. Daniel Glozman. "Our goal is to democratize this highly sophisticated procedure, enabling patients around the world to easily access the treatment that can restore their vision.
